Emilia Bulaevsky Zychlinsky
Direttore operativo presso Exai Bio, Inc.
Posizioni attive di Emilia Bulaevsky Zychlinsky
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Exai Bio, Inc.
 Exai Bio, Inc. Packaged SoftwareTechnology Services Exai Bio, Inc. is an American next-generation liquid biopsy company founded by Hani Goodarzi, Babak Alipanahi, and Patrick Arensdorf. The company's mission is to enable early detection, accurate diagnosis, personalized and targeted treatment, and ultimately cure of cancer. Exai Bio's proprietary RNA- and AI-based liquid biopsy technology delivers clinical insights into cancer biology to enable the earliest and most accurate diagnosis of cancer. Patrick Arensdorf has been the CEO since incorporation. | Direttore operativo | 02/02/2023 | - |
Storia della carriera di Emilia Bulaevsky Zychlinsky
Precedenti posizioni note di Emilia Bulaevsky Zychlinsky
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| DIADEXUS, INC. | Direttore Tecnico/Scientifico/R&S | 10/01/2011 | 01/04/2016 |
Minaris Medical America, Inc.
 Minaris Medical America, Inc. Medical SpecialtiesHealth Technology Minaris Medical America, Inc. manufactures the CLA and OPTIGEN Allergy Tests, in vitro diagnostic tests and alternative to skin tests. It serves the medical community through its Allos Reference Laboratory. The firm’s products include the CLA Allergen-Specific IgE Assay, theOPTIGEN Allergen-Specific IgE Assay, CLA-1 Luminometer In Vitro Allergy Diagnostic System and AP 720S Semi-Automated In Vitro Allergy Diagnostic System. The company is headquartered in Mountain View, CA. | Direttore Tecnico/Scientifico/R&S | - | - |
| Consigliere Generale | - | - | |
| STANDARD BIOTOOLS INC. | Consigliere Generale | 01/04/2016 | - |
Formazione di Emilia Bulaevsky Zychlinsky
| Stanford University | Doctorate Degree |
| Instituto Politecnico Nacional | Undergraduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 6 |
| Messico | 2 |
Posizioni
| Chief Tech/Sci/R&D Officer | 2 |
| General Counsel | 2 |
| Doctorate Degree | 1 |
Settori
| Health Technology | 4 |
| Consumer Services | 3 |
| Technology Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| STANDARD BIOTOOLS INC. | Health Technology |
| Aziende private | 3 |
|---|---|
Diadexus, Inc.
 Diadexus, Inc. BiotechnologyHealth Technology Diadexus, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio intends to treat cardiovascular diseases. The company was founded on November 27, 1995 and is headquartered in South San Francisco, CA. | Health Technology |
Minaris Medical America, Inc.
Minaris Medical America, Inc. Medical SpecialtiesHealth Technology Minaris Medical America, Inc. manufactures the CLA and OPTIGEN Allergy Tests, in vitro diagnostic tests and alternative to skin tests. It serves the medical community through its Allos Reference Laboratory. The firm’s products include the CLA Allergen-Specific IgE Assay, theOPTIGEN Allergen-Specific IgE Assay, CLA-1 Luminometer In Vitro Allergy Diagnostic System and AP 720S Semi-Automated In Vitro Allergy Diagnostic System. The company is headquartered in Mountain View, CA. | Health Technology |
Exai Bio, Inc.
Exai Bio, Inc. Packaged SoftwareTechnology Services Exai Bio, Inc. is an American next-generation liquid biopsy company founded by Hani Goodarzi, Babak Alipanahi, and Patrick Arensdorf. The company's mission is to enable early detection, accurate diagnosis, personalized and targeted treatment, and ultimately cure of cancer. Exai Bio's proprietary RNA- and AI-based liquid biopsy technology delivers clinical insights into cancer biology to enable the earliest and most accurate diagnosis of cancer. Patrick Arensdorf has been the CEO since incorporation. | Technology Services |
